Angle gains on breakthrough in cancer diagnostic technology

Angle advanced more than 90 per cent Monday after the medtech company announced a major breakthrough in its cancer diagnostic product Parsotix.

Angle advanced more than 90 per cent Monday after the medtech company announced a major breakthrough in its cancer diagnostic product Parsotix.

The AIM listed company said it had edged further in the development of Parsortix, a non-invasive technology which captures and counts rare circulating tumour cells (CTC) from the blood of cancer patients.

Angle has designed a process for recovering the captured calls from the Parsotix cassette. The cells are then analysed by a variety of contemporary molecular techniques.

CTC analysis, through the use of such techniques, extends the Parsortix technology's capability and opens up new diagnostic, prognostic and treatment applications for cancer patients.

Angle expects its market to grow as it is the first device designed to recover CTCs. Analysis of CTCs can be used to screen and diagnose patients.

The company said the technology monitors patients' response to treatment in a non-invasive manner without having to perform a tumour biopsy.

Angle's research partner, the Paterson Institute for Cancer Research, will be researching the potential for the Parsortix system.

Angle's Founder and Chief Executive, Andrew Newland, said: "This major development means that our system now offers two approaches to analysis of CTCs: counting and identification of cells captured within the cassette; and molecular analysis of cells recovered from the cassette as a liquid biopsy.

"We know from discussions with researchers and physicians that there is market demand for this versatility."

RD

Recommended

Broker safety – your questions answered
Investment strategy

Broker safety – your questions answered

Cris Sholto Heaton answers more of your questions about the safety of stockbroker accounts
25 Mar 2020
How demographics affects stock valuations
Investment strategy

How demographics affects stock valuations

New research suggests that stock and bond valuations are driven by the age of the population – at least in the US.
24 Feb 2020
Do you own shares in Sirius Minerals? Here’s what you need to do now
Stocks and shares

Do you own shares in Sirius Minerals? Here’s what you need to do now

Mining giant Anglo American has proposed a cash takeover of Yorkshire-based minnow Sirius Minerals. Unhappy shareholders must decide whether to accept…
20 Feb 2020
Why investors should be “cautiously bullish” for 2020
Stockmarkets

Why investors should be “cautiously bullish” for 2020

Analysts have been out in force making rosy predictions for stockmarkets in 2020, but while there is certainly a case for optimism, investors should r…
17 Jan 2020

Most Popular

The rising dollar is proving bad news for most other assets – will it last?
Investment strategy

The rising dollar is proving bad news for most other assets – will it last?

Precious metals, stocks and pretty much every other asset has taken a tumble as the US dollar strengthens. Dominic Frisby looks at how long this trend…
23 Sep 2020
The electric-car bubble could get an awful lot bigger from here
Renewables

The electric-car bubble could get an awful lot bigger from here

The switch to electric cars is driving a huge investment bubble. But that’s not necessarily a bad thing, says John Stepek. Fortunes will be made and l…
24 Sep 2020
Why you should stuff your end-of-pandemic portfolio with Chinese stocks
China stockmarkets

Why you should stuff your end-of-pandemic portfolio with Chinese stocks

For an end-of-pandemic portfolio, you need assets that can cope with today’s volatility. And that, says Merryn Somerset Webb, means Chinese stocks.
14 Sep 2020